About Ariosa Diagnostics
Ariosa Diagnostics is a company based in San Jose (United States) founded in 2008 was acquired by Roche in December 2014. Ariosa Diagnostics has raised $67.5 million across 3 funding rounds from investors including Roche and Venrock. The company has 246 employees as of December 31, 2014. Ariosa Diagnostics operates in a competitive market with competitors including Natera, BillionToOne, Progenity, SYNLAB and Beikang Medical, among others.
- Headquarter San Jose, United States
- Employees 246 as on 31 Dec, 2014
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ariosa Diagnostics Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Ariosa Diagnostics
Ariosa Diagnostics has successfully raised a total of $67.5M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $52.7 million completed in November 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ariosa Diagnostics
Ariosa Diagnostics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Roche and Venrock.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on tech sectors
|
Locked | Locked | Locked | |
|
Pharmaceuticals and diagnostics kits are developed for various diseases.
|
Locked | Locked | Locked |
Investor details for Ariosa Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ariosa Diagnostics
Investment portfolio details for Ariosa Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ariosa Diagnostics
Detailed financials for Ariosa Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ariosa Diagnostics Comparisons
Peer comparison for Ariosa Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ariosa Diagnostics
Ariosa Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Natera, BillionToOne, Progenity, SYNLAB and Beikang Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Provider of cell-free cancer liquid biopsy test
|
|
| Locked | Locked | Locked |
Non-invasive prenatal genomic testing is provided for genetic disorders.
|
|
| Locked | Locked | Locked |
Provider of medical diagnosis and clinical laboratory analysis services
|
|
| Locked | Locked | Locked |
NGS-based diagnostic solutions for neonatal screening are developed.
|
|
| Locked | Locked | Locked |
Non-invasive prenatal genetic tests and genomic services are provided.
|
Detailed competitors of Ariosa Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ariosa Diagnostics
Complete news archive for Ariosa Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ariosa Diagnostics
Ariosa Diagnostics was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Ariosa Diagnostics is headquartered in San Jose, United States. It is registered at San Jose, California, United States.
Ariosa Diagnostics is a funded company, having raised a total of $67.5M across 3 funding rounds to date.
As of Dec 31, 2014, the latest employee count at Ariosa Diagnostics is 246.
Ariosa Diagnostics was founded in 2008 in San Jose, United States, focusing on the molecular diagnostics sector. Operations are conducted through a CLIA-certified laboratory, where cell-free DNA in maternal blood is analyzed for prenatal risk assessment. The Harmony Prenatal Test, available from 10 weeks of pregnancy, evaluates risks of trisomies 13, 18, and 21. Acquisition by Roche occurred in December 2014.
Ariosa Diagnostics's top competitors include Natera, BillionToOne and Pictor.